Navigation Links
Recent NDRC Pricing Concessions Not Expected to Impact China Sky One's Portfolio of Products
Date:12/3/2010

HARBIN, China, Dec. 3, 2010 /PRNewswire-Asia-FirstCall/ -- China Sky One Medical, Inc. ("China Sky One Medical" or "the Company") (Nasdaq: CSKI), a leading fully integrated pharmaceutical company in the People's Republic of China ("PRC"), today announced that its profitability is not expected to be affected by recent price adjustments enforced by China's National Development and Reform Commission ("NDRC") as the Company does not have any products on the price cut list. Furthermore, the Company's ability to discretionarily price roughly 80% of current portfolio and pipeline products lessens the Company's exposure to potential future price cuts by the NDRC.

On November 29, 2010, Chinese NDRC announced a new round of price control measures, including price cuts on 174 drugs as well as cancellation of preferential pricing treatment on 16 drugs, effective December 12, 2010. The affected drugs have the following characteristics: 1) primarily off-patent products that are produced by foreign-owned or joint venture pharmaceutical companies, and 2) relatively mature drugs. With the purpose of encouraging innovation, these types of drugs have been priced separately since 2000 and are often several times more expensive than similar generics produced by domestic-funded enterprises. With an average 19% price cut, the Chinese government estimates that such measures could save 2 billion RMB per year for the public.

About China Sky One Medical, Inc. China Sky One Medical, Inc., a Nevada corporation, is a holding company. The Company engages in the manufacturing, marketing and distribution of pharmaceutical, medicinal and diagnostic products. Through its wholly-owned subsidiaries, Harbin Tian Di Ren Medical Science and Technology Company, Harbin First Bio-Engineering Company Limited, Heilongjiang Tianlong Pharmaceutical, Inc. and Peng Lai Jin Chuang Pharmaceutical Company, the Company manufactures and distributes over-the-counter pharmaceutical products, which make up its major revenue source. For more information, visit http://www.cski.com.cn.

Safe Harbor Statement

Certain of the statements made in the press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward- looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include financial projections or information regarding the Company's product portfolio and pricing freedom. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with the effect of changing economic conditions in The People's Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time.Investor Relations Contact:China Sky One Medical

CCG Investor RelationsStanley Hao, Vice President

Crocker Coulson, PresidentEmail: ir@cski.com.cn

Tel: +1-646-213-1915Email: crocker.coulson@ccgir.com Website: www.ccgirasia.com Mabel Zhang, Vice PresidentTel: +1-310-954-1353Email: mabel.zhang@ccgir.com
'/>"/>

SOURCE China Sky One Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Arena Pharmaceuticals Announces Third Quarter 2010 Financial Results and Reviews Recent Developments
2. Recent Patient Series Demonstrates Spirus Medicals Power Spiral Endoscope Enables Unprecedented Access to GI Tract
3. CareCentrix Appoints Chief Information Officer
4. Argos Therapeutics to Present Recent Clinical Developments and Corporate Overview at 18th Annual BioPartnering Europe
5. Lingohocken Fire Company Receives PAD Donation After Recent Rescue at Fox Heath Farm
6. Study of Brands Shows Tylenol Maintains Consumer Loyalty Despite Recent Quality Challenges
7. NeoStem Comments on Recent Court Ruling Blocking the Federal Governments Funding of Embryonic Stem Cell Research
8. Lost and Found: L2FU Recovers 100% of Clinical Trial Patients for Recent Pivotal Study
9. China Medical Technologies Announces the Recent Publication of a Study on its SPR Analyzer and HPV DNA Chip in Cancer Genetics and Cytogenetics and the Creation of a Medical Publications Column to the Investor Relations Section on its Website
10. Protege Encore Clinical Trial Evaluates New Investigational Approach For Individuals Recently Diagnosed With Type 1 Diabetes
11. Cardium Reports on Fourth Quarter and Year-End 2009 Financial Results and Recent Developments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... -- ResMed (NYSE: RMD ), BMC (Peking, ... Winter Haven, Florida ) gaben heute bekannt, dass ... globalen Rechtsstreitigkeiten zwischen den Parteien geeinigt haben. BMC und ... im Tausch gegen Lizenzgebühren an ResMed gestattet, und ResMed ... in Florida anhängige Rechtsverfahren zwischen ...
(Date:1/23/2017)... 2017 InDex Pharmaceuticals Holding AB (publ) today ... congress of the European Crohn,s and Colitis Organisation (ECCO). The ECCO ... focus on inflammatory bowel disease (IBD). The congress is held in ... ... to again having been selected to present data at the largest ...
(Date:1/21/2017)... DUBLIN , Jan 20, 2017 ... "US Clinical Laboratory Testing Market By Type of Test (Tumor, ... Independent), & By Type of Diseases (Tuberculosis, Influenza, Cancer, HIV/AIDS ... ... an attractive destination for healthcare services, market segments, especially clinical ...
Breaking Medicine Technology:
(Date:1/22/2017)... , ... January 22, 2017 , ... Zifam Pinnacle, an ... the world, recently met with big-name retail buyers at the January ECRM Trade Show ... efficacy and uses the utmost safety standards in all of its creations to help ...
(Date:1/21/2017)... FL (PRWEB) , ... January 21, 2017 , ... Caronlab ... recently attended the January ECRM Trade Show in Hilton Head, SC, where it benefited ... reputation for the quality of its beauty and wellness products. At this trade show, ...
(Date:1/21/2017)... ... 21, 2017 , ... Seamild, the largest manufacturer of oats in China, is ... and founder. As Oat is recognized globally as one of the healthiest cereals, XieQingkui, ... believes it is a move to sow the seed of good karma. Buddhism spirit ...
(Date:1/21/2017)... ... January 21, 2017 , ... Northern California Medical Associates (NCMA) ... their multi-specialty medical group. The dermatology practice provides general dermatologic treatment, outpatient surgery, ... add this excellent dermatology practice to our group’s medical services,” explains NCMA CEO, ...
(Date:1/21/2017)... ... 21, 2017 , ... The Nobel Biocare™ dental implant company ... for its creos™ line of bone regenerative products. Specifically, the Nobel ... utilizes creos™ allo.gain™ bone graft for a variety of bone reconstruction procedures. In ...
Breaking Medicine News(10 mins):